Worth reading
60In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
63.4
Year-on-year change in operating profit (%)Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)1 January 2026–30 June 2026ConsolidatedJapanese GAAPNet Sales2,636Millions of yenYear on year +9.3%Progress 36.6%
Operating profit17Millions of yenYear on year -63.4%Progress 3.4%
Ordinary income41Millions of yenYear on year +101.4%Progress 7.9%
Net income attributable to owners of the parent44Millions of yenYear on year -84.1%Progress 8.0%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥0.89
Financial position at period-end
Total assets11,091Millions of yen
of which net assets 8,425 Millions of yenEquity ratio 76.0%vs. prior year-end +6.6pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating-66
Investment-685
Financials-853
Net change-1,604
Stacked from zero: upward is an increase in cash, downward a decrease (in Millions of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period2,666 Millions of yen
Segment revenue
Pharmaceuticals Business2,52395.7%+14.3%
Infection-Control Business1114.2%-45.4%
Other businesses20.1%
Segment profit
Pharmaceuticals Business557-7.3%
Infection-Control Business-92
Other businesses-14
Regional salesCategory Pharmaceuticals business, domestic / Net Sales 1,410 Millions of yen / Year on year against the same period last year -16.9 Millions of yen, Category Pharmaceuticals business, overseas / Net Sales 1,112 Millions of yen / Year on year against the same period last year 118.7 Millions of yen, Category Infection control business, domestic over-the-counter / Net Sales 16 Millions of yen / Year on year against the same period last year Not disclosed, Category Infection control business, domestic professional-use / Net Sales 77 Millions of yen / Year on year against the same period last year Not disclosed, Category Infection control business, overseas / Net Sales 17 Millions of yen / Year on year against the same period last year Not disclosed
Outlook and shareholder returns
Full-year earnings forecast
Net Sales7,200 Millions of yen (YoY +12.5%)
Operating profit500 Millions of yen (YoY +8.9%)
Ordinary income520 Millions of yen (YoY +7.7%)
Net income550 Millions of yen (YoY -40.4%)
Annual Dividend Forecast¥3.3 → ¥3.5
Factors Behind Changes in Business Performance
Growth in overseas sales, higher advertising and promotion expenses related to overseas marketing initiatives, the absence of the foreign exchange losses and special gains recorded in the same period of the previous year, and improved profitability from reduced advertising and promotion expenses in the infection control business
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 / Excluded 0 / Company name None
Impairment loss0 Millions of yen
Breakdown of extraordinary income (loss)Extraordinary income Not disclosed / Extraordinary loss Item Impairment Losses / Amount 0 Millions of yen, Item Loss on Disposal of Fixed Assets / Amount 0 Millions of yen
Depreciation and amortization148 Millions of yen
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End50,636,900 Shares
Treasury Shares at Period-End328,819 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 June 2026 |
| Net Sales | 2,636 Millions of yen (YoY +9.3%) |
| Operating profit | 17 Millions of yen (YoY -63.4%) |
| Ordinary income | 41 Millions of yen (YoY +101.4%) |
| Profit attributable to owners of the parent | 44 Millions of yen (YoY -84.1%) |
| Net income per share | ¥0.89 |
| Equity ratio | End of the current fiscal period 76 / End of previous period 69.4 |
| Total assets | 11,091 Millions of yen |
| Net assets | 8,425 Millions of yen |
| Cash flows from operating activities | -66 Millions of yen |
| Cash flows from investing activities | -685 Millions of yen |
| Cash flows from financing activities | -853 Millions of yen |
| Cash and cash equivalents at end of period | 2,666 Millions of yen |
| Full-year earnings forecast | Net Sales 7,200 Millions of yen (YoY +12.5%) / Operating profit 500 Millions of yen (YoY +8.9%) / Ordinary income 520 Millions of yen (YoY +7.7%) / Net income 550 Millions of yen (YoY -40.4%) |
| Annual Dividend Forecast | ¥3.3 → ¥3.5 |
| Segment revenue | Segment Pharmaceuticals Business / Net Sales 2,523 Millions of yen / Year on year against the same period last year 14.3 Millions of yen, Segment Infection-Control Business / Net Sales 111 Millions of yen / Year on year against the same period last year -45.4 Millions of yen, Segment Other businesses / Net Sales 2 Millions of yen / Year on year against the same period last year Not disclosed |
| Segment profit | Segment Pharmaceuticals Business / Segment profit 557 Millions of yen / Year on year against the same period last year -7.3 Millions of yen, Segment Infection-Control Business / Segment profit -92 Millions of yen / Year on year against the same period last year Not disclosed / Additional information ¥59 million improvement year on year, Segment Other businesses / Segment profit -14 Millions of yen / Year on year against the same period last year Not disclosed |
| Regional sales | Category Pharmaceuticals business, domestic / Net Sales 1,410 Millions of yen / Year on year against the same period last year -16.9 Millions of yen, Category Pharmaceuticals business, overseas / Net Sales 1,112 Millions of yen / Year on year against the same period last year 118.7 Millions of yen, Category Infection control business, domestic over-the-counter / Net Sales 16 Millions of yen / Year on year against the same period last year Not disclosed, Category Infection control business, domestic professional-use / Net Sales 77 Millions of yen / Year on year against the same period last year Not disclosed, Category Infection control business, overseas / Net Sales 17 Millions of yen / Year on year against the same period last year Not disclosed |
| Depreciation and amortization | 148 Millions of yen |
| Impairment loss | 0 Millions of yen |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Item Impairment Losses / Amount 0 Millions of yen, Item Loss on Disposal of Fixed Assets / Amount 0 Millions of yen |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 50,636,900 Shares |
| Treasury Shares at Period-End | 328,819 Shares |
| Factors Behind Changes in Business Performance | Growth in overseas sales, higher advertising and promotion expenses related to overseas marketing initiatives, the absence of the foreign exchange losses and special gains recorded in the same period of the previous year, and improved profitability from reduced advertising and promotion expenses in the infection control business |
Items this document does not state (6)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicyOrders received and order backlogMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales increased on growth in overseas sales to China, Hong Kong and Taiwan, among other markets, while operating income declined due to higher advertising and promotion expenses related to overseas marketing initiatives. Ordinary income increased because no foreign exchange loss was recorded, unlike in the same period of the previous year, and because interest income and foreign exchange gains were recognized. Interim net income attributable to owners of the parent declined due to the absence of the ¥347 million gain on the sale of investment securities and the ¥14 million compensation received recorded in the same period of the previous year.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.